CRACD

Across TCGA pan-cancer cohorts, CRACD Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated CRACD data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CRACD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CRACD expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

STAD, UCEC, and ACC are the cancer types where CRACD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.248	0.739	<.001	24	view →
UCEC	DFS	Median	II,III,IV	0.905	0.297	.004	24	view →
ACC	OS	Median	All	0.273	0.802	.017	15	view →
ESCA	DFS	Median	II,III,IV	0.253	0.530	.027	9	view →
SCLC	DFS	Median	IV	0.110	0.446	.010	6	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →
HNSC	OS	Median	All	0.456	0.688	.040	3	view →
LUAD	DFS	Median	III,IV	0.501	0.398	.002	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

CRACD–STAD (OS)

Open the STAD breakdown →